Failure Analysis, Product Recalls, and Liability: Preventative Measures to Help Prevent the FDA from Knocking on Your Door
Event | 01.29.13, 12:00 AM UTC - 12:00 AM UTC
Join us for an interactive discussion on medical device/biotech design analysis, regulatory compliance, and liability issues.
The current regulatory and litigation environments in the United States require that potential safety issues and problems with mass-produced products be vigorously investigated and quickly remedied.
How well a company manages a recall situation or deals with compliance problems (identified, for example, in a FDA Form 483 or Warning Letter) can affect not only the future viability of the product and the company’s liability and financial status, but the company’s reputation and "brand equity."
A company’s success in responding to FDA concerns and communicating with the agency, customers, and health-care professionals, can significantly impact public perceptions and potential liability. In addition, determining whether a device failure has occurred, and identifying and correcting its cause, are critical to avoiding government-imposed shut-downs, getting a product back on the market after a recall, and helping to avoid litigation.
We invite you to join Exponent, a leading consulting firm providing design, failure analysis, and recall support to biotech companies, and Crowell & Moring, LLP, a trusted and respected international law firm with deep and broad expertise in FDA compliance and products liability counseling and litigation defense, for an interactive discussion on these medical device/biotech design analysis, regulatory compliance, and liability issues.
Seminar topics will include:
- How to Use the FDA Regulated Design Process to Manage Risk: Elements of Design Controls and Why It Matters
- Materials Compatibility and Devices – Considerations and Consequences
- Applying Human Factors in Design / Labeling / Instructions
For more information, please visit these areas: Product Risk Management
Insights
Event | 02.20.25
Has the Buss Stopped? Recoupment Today
Has the Buss Stopped? Recoupment Today: In 1997, the California Supreme Court decided Buss v. Superior Court. In Buss, the court concluded that a liability insurer that defended a mixed action could seek reimbursement from the insured for the defense costs associated with the claims that were not even potentially covered. Since then, numerous courts have held that insurers are entitled to recoup their defense costs associated with uncovered claims or causes of action. On the other hand, a significant number of courts have rejected insurers’ right to recoupment, at least in the absence of a policy provision granting the insurer that right. Some commentators have even suggested that the current judicial trend might be away from permitting insurers to recoup their defense costs. Is that correct? Has the Buss stopped? This panel of coverage experts will analyze insurers’ claimed right to recoupment today, and offer their perspectives on what the law on recoupment should perhaps be and might be in the future.
Event | 02.18.25 - 02.20.25
Event | 12.05.24
Event | 12.05.24